Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 2.86 percent increase over losses of $(0.70) per share from the same period last year.
Breaking: New York Expands Cannabis Licensing After Legal Delays And Tug Of War Between David And Goliath
New York's cannabis landscape is set for a significant transformation.